Autopsy report · NCT04970719

Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus

“adequate cases were not available”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders

Sponsor type

University, hospital or other

Conditions

COVID-19 Pneumonia

Interventions

Baricitinib; Dexamethasone; Remdesivir

Participants

0

Sites

7

Countries

Bangladesh

Trials that died the same way

• Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy
  “poor case accural” (65% match in meaning)
• Effects of Miglustat Therapy on Infantile Type of Sandhoff and Taysachs Diseases (EMTISTD)
  “The number of controls was insufficient compared to case.” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.